AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
Rhea-AI Summary
AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares. This purchase reflects the Chairman's confidence in the company’s future, as AccuStem focuses on developing innovative molecular testing for cancer diagnostics aimed at improving patient outcomes. The company is dedicated to addressing critical clinical needs throughout cancer screening, treatment, and monitoring.
Positive
- Chairman Gabriele Cerrone increased his stake in the company by purchasing 24,500 shares, a sign of confidence in ACUT's future.
- Total shares held by Cerrone now stand at 3,855,723, indicating strong insider commitment.
Negative
- None.
News Market Reaction – ACUT
In the trading session that priced this news, ACUT declined 13.99%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 24,500 ACUT shares in the open market. This brings his total holding to 3,855,723 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.
Media Contact:
Jeff Fensterer
Phone: 415-640-6010
Email: jeff@accustem.com
Investor Contact:
Wendy Blosser
Email: investors@accustem.com
